565 related articles for article (PubMed ID: 8183238)
21. Mutational analysis of the potential phosphorylation sites for protein kinase C on the CCK(A) receptor.
Smeets RL; Fouraux MA; Pouwels W; van Emst-de Vries SE; Ronken E; De Pont JJ; Willems PH
Br J Pharmacol; 1998 Jul; 124(5):935-45. PubMed ID: 9692779
[TBL] [Abstract][Full Text] [Related]
22. Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells.
Klueppelberg UG; Molero X; Barrett RW; Miller LJ
Mol Pharmacol; 1990 Aug; 38(2):159-63. PubMed ID: 2200953
[TBL] [Abstract][Full Text] [Related]
23. CCK-JMV-180: a peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors.
Stark HA; Sharp CM; Sutliff VE; Martinez J; Jensen RT; Gardner JD
Biochim Biophys Acta; 1989 Feb; 1010(2):145-50. PubMed ID: 2463851
[TBL] [Abstract][Full Text] [Related]
24. Photoaffinity-labeled ligand binding domains on dopamine transporters identified by peptide mapping.
Vaughan RA
Mol Pharmacol; 1995 May; 47(5):956-64. PubMed ID: 7746282
[TBL] [Abstract][Full Text] [Related]
25. Characterization of cholecystokinin receptor sites in guinea-pig cortical membranes using [125I]Bolton Hunter-cholecystokinin octapeptide.
Lin CW; Miller T
J Pharmacol Exp Ther; 1985 Mar; 232(3):775-80. PubMed ID: 2983069
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
27. The efficiency of covalent labeling of the pancreatic cholecystokinin receptor using a battery of crosslinkable and photolabile probes.
Klueppelberg UG; Powers SP; Miller LJ
Receptor; 1990-1991 Winter; 1(1-2):1-11. PubMed ID: 2152369
[TBL] [Abstract][Full Text] [Related]
28. Direct identification of the agonist binding site in the human brain cholecystokininB receptor.
Anders J; Blüggel M; Meyer HE; Kühne R; ter Laak AM; Kojro E; Fahrenholz F
Biochemistry; 1999 May; 38(19):6043-55. PubMed ID: 10320330
[TBL] [Abstract][Full Text] [Related]
29. Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor.
Pearson RK; Miller LJ; Hadac EM; Powers SP
J Biol Chem; 1987 Oct; 262(28):13850-6. PubMed ID: 3654639
[TBL] [Abstract][Full Text] [Related]
30. Two functionally distinct cholecystokinin receptors show different modes of action on Ca2+ mobilization and phospholipid hydrolysis in isolated rat pancreatic acini. Studies using a new cholecystokinin analog, JMV-180.
Matozaki T; Göke B; Tsunoda Y; Rodriguez M; Martinez J; Williams JA
J Biol Chem; 1990 Apr; 265(11):6247-54. PubMed ID: 1690723
[TBL] [Abstract][Full Text] [Related]
31. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
[TBL] [Abstract][Full Text] [Related]
32. The cholecystokinin analogues JMV-180 and CCK-8 stimulate phospholipase C through the same binding site of CCK(A) receptor in rat pancreatic acini.
Sarri E; Ramos B; Salido GM; Claro E
Br J Pharmacol; 2001 Aug; 133(8):1227-34. PubMed ID: 11498507
[TBL] [Abstract][Full Text] [Related]
33. The biochemical characterization of the native pancreatic cholecystokinin receptor using affinity labeling approaches.
Miller LJ
Yale J Biol Med; 1992; 65(5):441-8; discussion 465-9. PubMed ID: 1340061
[TBL] [Abstract][Full Text] [Related]
34. A carboxyl-terminally truncated mutant and nonglycosylated A2a adenosine receptors retain ligand binding.
Piersen CE; True CD; Wells JN
Mol Pharmacol; 1994 May; 45(5):861-70. PubMed ID: 8190103
[TBL] [Abstract][Full Text] [Related]
35. Stimulation of pancreatic growth by cholecystokinin is mediated by high affinity receptors on rat pancreatic acinar cells.
Dawra R; Saluja A; Lerch MM; Saluja M; Logsdon C; Steer M
Biochem Biophys Res Commun; 1993 Jun; 193(3):814-20. PubMed ID: 8323557
[TBL] [Abstract][Full Text] [Related]
36. Biochemical characterization of a subtype pancreatic cholecystokinin receptor and of its agonist binding domain.
Poirot SS; Dufresne M; Jiménez J; Vaysse N; Fourmy D
J Recept Res; 1992; 12(2):233-53. PubMed ID: 1583623
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors.
Cappelli A; Anzini M; Vomero S; Menziani MC; De Benedetti PG; Sbacchi M; Clarke GD; Mennuni L
J Med Chem; 1996 Feb; 39(4):860-72. PubMed ID: 8632410
[TBL] [Abstract][Full Text] [Related]
39. The gall bladder cholecystokinin receptor exists in two guanine nucleotide-binding protein-regulated affinity states.
Molero X; Miller LJ
Mol Pharmacol; 1991 Feb; 39(2):150-6. PubMed ID: 1899903
[TBL] [Abstract][Full Text] [Related]
40. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
